| In refractory patients with aplastic anemia, in whom an immunosuppressive therapy has failed, an attempt could be made to administer ivIg with some prospect of success. | 2 C |
| Note: Because this indication is not licensed, the application would be done in the ‘off-label use’. The legal issues involved in this are pointed out in section 0.4. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.